33 results
6-K
EX-99.1
MOR
Morphosys AG
13 Dec 21
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
10:14am
endpoint was conversion to transfusion independence (TI) for 12 consecutive weeks. In the non-TD cohort, the primary endpoint was SVR35 at week 24. At week … 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B
6-K
EX-99.1
MOR
Morphosys AG
14 Jun 23
Current report (foreign)
7:28am
. The primary endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks
6-K
EX-99
MOR
Morphosys AG
12 Dec 22
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
6:04am
to transfusion independence for 12 consecutive weeks. The primary endpoint for patients in cohorts 1B and 2B, who were not TD at baseline, is the proportion
6-K
EX-99.1
MOR
Morphosys AG
10 Jun 22
Current report (foreign)
7:16am
for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks. The primary endpoint
6-K
EX-99.1
MOR
Morphosys AG
4 Apr 23
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
4:09pm
endpoint for the patients in cohorts 1A and 2A, who were TD at baseline, is conversion to transfusion independence for 12 consecutive weeks
6-K
EX-99.1
psskak
11 May 23
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
1:12pm
6-K
EX-99.1
y31 x18xsitms9go
2 Nov 23
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
9:20am
6-K
EX-99.1
l2zysu
4 Nov 21
Current report (foreign)
9:50am
6-K
EX-99.1
wgi ksyb136546ksd
23 Jun 22
First Quarter Interim Statement JANUARY – MARCH
6:30am
6-K
EX-99.1
zsotns
3 Nov 22
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
9:40am
6-K
EX-99.1
r46k8l6ny3dckti5v
16 Nov 22
Third Quarter Interim Statement January – September
4:14pm
6-K
EX-99.1
e85360j4zlqs5
16 Mar 22
Current report (foreign)
5:13pm
6-K
EX-99.1
kfxy6 hzegzk
23 Mar 22
Current report (foreign)
4:15pm
6-K
EX-99.1
39econitnoz
20 Mar 24
Current report (foreign)
4:12pm
6-K
EX-99.1
xmo8cm 4axzuvbj
23 Mar 21
Current report (foreign)
3:53pm
6-K
EX-99.1
5wmna4w
3 Aug 22
Half-Year Report JANUARY – JUNE 2022
4:36pm
6-K
EX-99.1
x11z3q z773jz65zhv7k
4 May 23
First Quarter Interim Statement January – March
9:24am
6-K
EX-99.1
o4g vyy3a60w
16 Nov 23
Third Quarter Interim Statement JANUARY – SEPTEMBER 2023
6:00am
6-K
EX-99.1
h5r8 62yxvrtr25
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
6-K
EX-99.1
mgxhs c6fi
27 Mar 20
Current report (foreign)
3:29pm